Trial: A Study to Compare Sacituzumab Tirumote…

Trial Details

Sponsor: Merck Sharp & Dohme LLC (industry)

Phase: 3

Start date: July 24, 2024

Planned enrollment: 686

Trial ID: NCT06459180

More trial details at ClinicalTrials.gov

Show Summary from Sponsor

Investigational Drug AI Analysis

Show for: Sacituzumab tirumotecan (SKB264, MK-2870, sac-TMT)

Overview

Sacituzumab tirumotecan (sac-TMT; SKB264; MK-2870) is an investigational antibody–drug conjugate (ADC) being evaluated across multiple solid tumors. The most mature evidence comes from randomized studies in previously treated metastatic triple-negative breast cancer (TNBC) and EGFR-mutated non-small-cell lung cancer (NSCLC). Earlier-phase activity has also been reported in hormone-receptor-positive breast, urothelial, endometrial, ovarian, cervical, gastric and other cancers. (nature.com)

Mechanism of action

Sac-TMT consists of a humanized antibody targeting TROP2, a cell-surface protein frequently overexpressed by epithelial cancers, conjugated through a hydrolytically cleavable linker to KL610023, a belotecan-derived topoisomerase I inhibitor. Its average drug-to-antibody ratio is approximately 7.4. After TROP2 binding and internalization, KL610023 is released and inhibits topoisomerase I, causing DNA damage and tumor-cell death. (frontiersin.org)

Efficacy

Metastatic TNBC: In the 263-patient phase 3 OptiTROP-Breast01 trial, sac-TMT improved median progression-free survival versus physician’s-choice chemotherapy: 6.7 vs 2.5 months (hazard ratio 0.32). Objective response rates were 45.4% vs 12.0%, and median response durations were 7.1 vs 3.0 months. At the interim overall-survival analysis, median survival was not reached with sac-TMT versus 9.4 months with chemotherapy (hazard ratio 0.53). (nature.com)
EGFR-mutated NSCLC: In a randomized Chinese trial of 137 patients previously treated with an EGFR inhibitor and platinum chemotherapy, sac-TMT produced an objective response rate of 45%, compared with 16% for docetaxel. Median progression-free survival was 6.9 vs 2.8 months (hazard ratio 0.30), while 12-month overall survival was 73% vs 54%. (pubmed.ncbi.nlm.nih.gov)
Other tumors: Preliminary single-arm studies have reported responses in urothelial cancer—confirmed response rates of 45.5% in second line and 26.3% in third or later lines—and in previously treated endometrial cancer, where the response rate was 34.1%**. These small, non-randomized cohorts require confirmation. (ascopubs.org)

Safety

Toxicity is predominantly hematologic. In the TNBC phase 3 trial, hematologic toxicity was the most common treatment-related adverse-event category. In an earlier 59-patient TNBC cohort, 57.6% experienced grade 3 or worse treatment-related events, most commonly decreased neutrophils (25.4%), decreased white-cell counts (23.7%), anemia (22.0%) and decreased platelets (16.9%); no treatment-related deaths, interstitial lung disease or grade 3 or worse diarrhea were reported. (nature.com)

In the randomized EGFR-mutated NSCLC study, grade 3 or worse treatment-related adverse events occurred in 56% of sac-TMT recipients versus 72% with docetaxel. Longer follow-up and broader international experience remain important for defining uncommon or delayed toxicities. (pubmed.ncbi.nlm.nih.gov)

TrialFetch AI Analysis

Goal: Determine whether second-line sacituzumab tirumotecan improves overall survival versus physician’s-choice treatment in recurrent or metastatic cervical cancer, both in patients with high TROP2 expression and in the overall population.

Patients: Adults assigned female sex at birth with measurable recurrent or metastatic cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma that progressed after one platinum-doublet regimen, with or without bevacizumab. Prior anti-PD-1 or anti-PD-L1 therapy, ECOG performance status 0–1, adequate organ function, and tumor tissue are required. Key exclusions include active CNS metastases, clinically significant neuropathy, inflammatory bowel disease, and current or prior steroid-treated pneumonitis or interstitial lung disease.

Design: Multicenter, open-label study with an initial sacituzumab tirumotecan safety run-in followed by a randomized, active-controlled phase 3 comparison.

Treatments: Sacituzumab tirumotecan 4 mg/kg is given intravenously every two weeks until progression or discontinuation. This investigational antibody–drug conjugate targets TROP2 and delivers a topoisomerase I inhibitor that causes DNA damage after cellular uptake. Randomized trials in other cancers have shown improved progression-free survival versus chemotherapy, but benefit in cervical cancer remains unconfirmed. The comparator is physician’s choice of intravenous pemetrexed, tisotumab vedotin, topotecan, vinorelbine, gemcitabine, or irinotecan, administered on drug-specific schedules.

Outcomes: The phase 3 primary endpoint is overall survival. Secondary endpoints include centrally reviewed progression-free survival, objective response rate and duration of response, adverse events, treatment discontinuation due to adverse events, and patient-reported quality of life and functioning. The run-in primarily assesses objective response and safety.

Burden on patient: Moderate. Treatment requires recurring infusion visits every two weeks with sacituzumab tirumotecan; comparator schedules range from visits every three weeks to multiple visits within a cycle. Patients must provide tumor tissue from a biopsy of a nonirradiated lesion, and trial participation entails imaging, safety assessments, and quality-of-life questionnaires over prolonged follow-up. No intensive pharmacokinetic sampling is specified.

Last updated: Sep 2026

Eligibility

Caution: ClinicalTrials.gov appears to have newer eligibility criteria than the version saved here. Review the current criteria in ClinicalTrials.gov.

Show Criteria

Inclusion Criteria:

* Has histologically-confirmed diagnosis of squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix

* Must have recurrent or metastatic cervical cancer that has progressed on or after treatment with 1 prior line of systemic platinum doublet chemotherapy (with or without bevacizumab) AND must have received anti-PD-1/anti-PD-L1 therapy as part of prior cervical cancer regimens

* Has measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, as assessed by the investigator. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions

* Is assigned female sex at birth, at least 18 years of age at the time of providing the informed consent

* Has ECOG performance status of 0 or 1 within 7 days before allocation for the Sacituzumab Tirumotecan Run-in or within 7 days before randomization for the Phase 3 portion

* Has provided tumor tissue (most recent sample is preferred) from a core or excisional biopsy of a tumor lesion not previously irradiated

* HIV-infected participants must have well controlled human immunodeficiency virus (HIV) on antiretroviral therapy (ART)

* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation (Sacituzumab Tirumotecan Run-in) or randomization (Phase 3 portion)

* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening

* Has adequate organ function

Exclusion Criteria:

* Has Grade ≥2 peripheral neuropathy

* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing

* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)

* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease.

* Received prior systemic anticancer therapy

* Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids

* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed

* Has histological subtypes of cervical cancer other than squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma (eg, carcinosarcoma) or nonepithelial cancer (eg, sarcoma, neuroendocrine tumors)

* Known additional malignancy that is progressing or has required active treatment within the past 3 years

* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis

* Active infection requiring systemic therapy

* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease

* Concurrent active Hepatitis B and active Hepatitis C virus infection

* Severe hypersensitivity (≥Grade 3) to sacituzumab tirumotecan or treatment of physician's choice (TPC) and/or any of their excipients, or other biologic therapy

* Participants who have not adequately recovered from major surgery or have ongoing surgical complications

* Has a history of (noninfectious) pneumonitis/ILD that required steroids or has current pneumonitis/ILD

Sites (240)

Sort by distance to:

Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0109)

CABA, C1431FWO, Argentina

No email / +549 1152990000

Status: Recruiting

Hospital Británico de Buenos Aires-Oncology ( Site 0102)

Ciudad Autónoma de Buenos Aires, Buenos Aires, C1280AEB, Argentina

No email / +541143096400

Status: Recruiting

Instituto de Investigaciones Clínicas Mar del Plata ( Site 0107)

Mar del Plata, Buenos Aires, B7600FZO, Argentina

No email / 92235937663

Status: Recruiting

Instituto Alexander Fleming ( Site 0108)

Buenos Aires, Buenos Aires F.D., C1426ANZ, Argentina

No email / +54-911-3665-3009

Status: Recruiting

Instituto de Oncología Angel H. Roffo ( Site 0103)

Buenos Aires, Buenos Aires F.D., C1417, Argentina

No email / 5491167281601

Status: Recruiting

Sanatorio Allende - Cerro-Oncology ( Site 0106)

Córdoba, Córdoba Province, 5000, Argentina

No email / 0810-555-2553

Status: Recruiting

Blacktown Hospital ( Site 3006)

Sydney, New South Wales, 2148, Australia

No email / +61286705108

Status: Recruiting

Campbelltown Hospital-Macarthur Cancer Therapy Centre Medical Oncology ( Site 3000)

Sydney, New South Wales, 2560, Australia

No email / +61246344342

Status: Recruiting

Royal Brisbane and Women's Hospital ( Site 3001)

Herston, Queensland, 4029, Australia

No email / +61736470372

Status: Recruiting

Monash Health-Oncology Research ( Site 3002)

Clayton, Victoria, 3168, Australia

No email / +61491299561

Status: Recruiting

Medizinische Universität Wien ( Site 1001)

Vienna, 1090, Austria

No email / +4314040061030

Status: Recruiting

Medizinische Universität Graz-Abteilung für Gynäkologie / Onkologie ( Site 1003)

Graz, Styria, 8036, Austria

No email / +4331638581081

Status: Recruiting

Medizinische Universitaet Innsbruck-Univ.-Klinik f. Gynäkologie und Geburtshilfe ( Site 1000)

Innsbruck, Tyrol, 6020, Austria

No email / 4351250482403

Status: Recruiting

Kepler Universitätsklinikum-Department for Oncology and Hematology ( Site 1002)

Linz, Upper Austria, 4020, Austria

No email / +43576808373652

Status: Recruiting

CHU UCL Namur/Site Sainte Elisabeth-Trial Office ( Site 2902)

Namur, 5000, Belgium

No email / 003281702824

Status: Recruiting

AZORG Campus Aalst-Moorselbaan ( Site 2905)

Aalst, Oost-Vlaanderen, 9300, Belgium

No email / +3253727002

Status: Recruiting

UZ Leuven-Gynecologic Oncology ( Site 2900)

Leuven, Vlaams-Brabant, 3000, Belgium

No email / +32 16 34 64 51

Status: Recruiting

Americas Centro de Oncologia Integrado ( Site 0202)

Rio de Janeiro, 22775-001, Brazil

No email / 552123990213

Status: Recruiting

Hospital Paulistano ( Site 0209)

São Paulo, 01321-001, Brazil

No email / +551131411083

Status: Recruiting

Instituto do Câncer e Transplante de Curitiba ( Site 0205)

Curitiba, Paraná, 80510130, Brazil

No email / +5541992620036

Status: Recruiting

Hospital Moinhos de Vento-Centro de Pesquisa Clínica ( Site 0204)

Porto Alegre, Rio Grande do Sul, 90035-001, Brazil

No email / +555135378258

Status: Recruiting

Centro de Hematologia e Oncologia ( Site 0203)

Joinville, Santa Catarina, 89202-050, Brazil

No email / 554734331819

Status: Recruiting

IBCC - Instituto Brasileiro de Controle do Câncer-Centro de Pesquisa Clínica ( Site 0200)

São Paulo, São Paulo, 04014-002, Brazil

No email / +551144500300

Status: Recruiting

Complex Oncology Center - Plovdiv EOOD ( Site 1102)

Plovdiv, 4004, Bulgaria

No email / 35970016120

Status: Recruiting

MHAT - Heart and Brain ( Site 1100)

Pleven, 5804, Bulgaria

No email / 35964678400

Status: Recruiting

MBAL Uni Hospital-Department of Medical Oncology ( Site 1104)

Panagyurishte, Pazardzhik, 4500, Bulgaria

No email / 35935788581

Status: Recruiting

BC Cancer Kelowna ( Site 4007)

Kelowna, British Columbia, V1Y 5L3, Canada

No email / +1 250-712-3996

Status: Recruiting

BC Cancer Surrey ( Site 4006)

Surrey, British Columbia, V3V 1Z2, Canada

No email / 604-930-2098

Status: Recruiting

BC Cancer Victoria ( Site 4008)

Victoria, British Columbia, V8R 6V5, Canada

No email / 250-519-5500

Status: Recruiting

Hamilton Health Sciences-Juravinski Cancer Centre ( Site 4003)

Hamilton, Ontario, L8V 5C2, Canada

No email / 905-387-9495 x 64417

Status: Recruiting

Royal Victoria Regional Health Centre ( Site 4009)

Barrie, Ontario, L4M 6M2, Canada

No email / 705 728-9090x66228

Status: Recruiting

Centre Hospitalier de l'Université de Montréal ( Site 4001)

Montreal, Quebec, H2X 0C1, Canada

No email / 514-890-8000 x 30777

Status: Recruiting

Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 4002)

Québec, Quebec, G1J 1Z4, Canada

No email / 418-525-4444 p 67322

Status: Recruiting

McGill University Health Centre ( Site 4000)

Montreal, Quebec, H4A 3J1, Canada

No email / 514 934 1934 x31975

Status: Recruiting

FALP-UIDO ( Site 0300)

Santiago, Region M. de Santiago, 7500921, Chile

No email / +56227067539

Status: Recruiting

Pontificia Universidad Catolica de Chile ( Site 0302)

Santiago, Region M. de Santiago, 832000, Chile

No email / +56223543334

Status: Recruiting

Anhui Provincial Cancer Hospital-Gynecological Oncology ( Site 5040)

Hefei, Anhui, 230000, China

No email / 0551 65329163

Status: Recruiting

Anhui Provincial Hospital ( Site 5011)

Hefei, Anhui, 230071, China

No email / 0551 62283760

Status: Recruiting

Beijing Peking Union Medical College Hospital ( Site 5045)

Beijing, Beijing Municipality, 100730, China

No email / +8601069154116

Status: Recruiting

Chongqing University Cancer Hospital ( Site 5003)

Chongqing, Chongqing Municipality, 400030, China

No email / 02365075621

Status: Recruiting

Affiliated Hospital of Guangdong Medical University ( Site 5004)

Zhanjiang, Guangdong, 524004, China

No email / 860759-2369606

Status: Recruiting

Guangxi Medical University Affiliated Tumor Hospital ( Site 5016)

Nanning, Guangxi, 530200, China

No email / 8607715331955

Status: Recruiting

Henan Cancer Hospital ( Site 5026)

Zhengzhou, Henan, 450008, China

No email / 0371 65587418

Status: Recruiting

The First Affiliated Hospital of Xinxiang Medical University-Oncology ( Site 5041)

Xinxiang, Henan, 453100, China

No email / 0373-4404384

Status: Recruiting

Hubei Cancer Hospital-Hubei Cancer Hospital ( Site 5019)

Wuhan, Hubei, 430079, China

No email / +86 027-87676792

Status: Recruiting

Wuhan Union Hospital ( Site 5020)

Wuhan, Hubei, 430048, China

No email / +862783261400

Status: Recruiting

Hunan Cancer Hospital ( Site 5021)

Changsha, Hunan, 410013, China

No email / +86 0731-88651900

Status: Recruiting

Xiangya Hospital Central South University ( Site 5009)

Changsha, Hunan, 410028, China

No email / 0731-84327458

Status: Recruiting

Jiangxi Maternal and Child Health Hospital ( Site 5031)

Nanchang, Jiangxi, 330077, China

No email / 86079186224432

Status: Recruiting

Jilin Province Tumor Hospital ( Site 5036)

Changchun, Jilin, 130000, China

No email / 86043185872600

Status: Recruiting

Shanxi Cancer Hospital ( Site 5043)

Taiyuan, Shanxi, 030000, China

No email / 8603514881611

Status: Recruiting

West China Second University Hospital, Sichuan University ( Site 5017)

Chengdu, Sichuan, 610000, China

No email / 028-88570307

Status: Recruiting

Women s Hospital School of Medicine Zhejiang University ( Site 5022)

Hangzhou, Zhejiang, 310006, China

No email / 86057187061501

Status: Recruiting

Zhejiang Cancer Hospital ( Site 5008)

Hangzhou, Zhejiang, 310022, China

No email / +86057188128112

Status: Recruiting

Groupe Hospitalier Diaconesses Croix Saint Simon ( Site 1506)

Paris, 75020, France

No email / +33144741008

Status: Recruiting

CENTRE LEON BERARD ( Site 1505)

Lyon Cedex08, Auvergne-Rhône-Alpes, 69373, France

No email / +33478782828

Status: Recruiting

Hopitaux Universitaires de Strasbourg ( Site 1501)

Strasbourg, Bas-Rhin, 67200, France

No email / +33368767141

Status: Recruiting

Institut Paoli-Calmettes ( Site 1504)

Marseille, Bouches-du-Rhone, 13009, France

No email / +33 4 91 22 36 77

Status: Recruiting

CHU Besançon ( Site 1507)

Besançon, Franche-Comte, 25030, France

No email / +33370632089

Status: Recruiting

Gustave Roussy ( Site 1512)

Villejuif, Île-de-France Region, 94805, France

No email / +33142114211

Status: Recruiting

Universitaetsklinikum Hamburg-Eppendorf-Department of Gynecology ( Site 1611)

Hamburg, 20246, Germany

No email / 0049 40741052510

Status: Recruiting

Diakonie-Klinikum Schwaebisch-Hall gGmbH Frauenklinik ( Site 1614)

Schwäbisch Hall, Baden-Wurttemberg, 74523, Germany

No email / +497917534640

Status: Recruiting

SLK-Kliniken Heilbronn ( Site 1617)

Heilbronn, Baden-Wurttemberg, 74078, Germany

No email / +49 7131-4934500

Status: Recruiting

Universitaetsklinikum Heidelberg Nationales Centrum fuer Tumorerkrankungen ( Site 1612)

Heidelberg, Baden-Wurttemberg, 69120, Germany

No email / 00 496221 56 38108

Status: Recruiting

Klinikum der Universität München Großhadern-Klinik und Poliklinik für Frauenheilkunde und Geburtshi ( Site 1605)

Munich, Bavaria, 81377, Germany

No email / +49 89440073723

Status: Recruiting

Universitätsklinikum Marburg ( Site 1604)

Marburg, Hesse, 35043, Germany

No email / +4964215861819

Status: Recruiting

Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung-Klinik für Gynäkologie und Gynäkologische Onko ( Site 1600)

Essen, North Rhine-Westphalia, 45136, Germany

No email / +4920117434001

Status: Recruiting

Universitaetsklinikum Duesseldorf-Klinik für Frauenheilkunde & Geburtshilfe ( Site 1607)

Düsseldorf, North Rhine-Westphalia, 40225, Germany

No email / 00492118117506

Status: Recruiting

Universitaetsklinikum Essen ( Site 1613)

Essen, North Rhine-Westphalia, 45147, Germany

No email / 00492017232575

Status: Recruiting

Klinikum Worms ( Site 1619)

Worms, Rhineland-Palatinate, 67550, Germany

No email / +4962415010

Status: Recruiting

Universitaetsklinikum des Saarlandes ( Site 1618)

Homburg, Saarland, 66421, Germany

No email / 0049 6841 1628101

Status: Recruiting

ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1703)

Chaïdári, Attica, 124 62, Greece

No email / +302313301848

Status: Recruiting

Aretaieio Hospital ( Site 1700)

Athens, Attica, 115 28, Greece

No email / +302107286444

Status: Recruiting

Mitera Hospital ( Site 1702)

Athens, Attica, 151 23, Greece

No email / +302106867551

Status: Recruiting

Agios Andreas Hospital Patras ( Site 1701)

Patras, Peloponnese, 263 35, Greece

No email / +302613601000

Status: Recruiting

Edith Wolfson Medical Center ( Site 2003)

Holon, 5810001, Israel

No email / +972522801565

Status: Recruiting

Hadassah Medical Center ( Site 2000)

Jerusalem, 9112001, Israel

No email / +97226777333

Status: Recruiting

Rambam Health Care Campus ( Site 2002)

Haifa, 3109601, Israel

No email / 04-7776234

Status: Recruiting

Sheba Medical Center ( Site 2001)

Ramat Gan, 5265601, Israel

No email / +97235303030

Status: Recruiting

Azienda Ospedaliera Spedali Civili di Brescia-Obstetrics anf gynecology ( Site 2110)

Brescia, 25123, Italy

No email / +390303998428

Status: Recruiting

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Ginecologia Oncologica ( Site 2102)

Roma, 00168, Italy

No email / +390630158545

Status: Recruiting

Istituto Europeo di Oncologia IRCCS ( Site 2108)

Milan, 20141, Italy

No email / +390257482540

Status: Recruiting

Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 2103)

Naples, 80131, Italy

No email / +390815903637

Status: Recruiting

Istituto Oncologico Veneto IRCCS ( Site 2109)

Padova, 35128, Italy

No email / +390498215729

Status: Recruiting

Ospedale Cannizzaro ( Site 2104)

Catania, 95126, Italy

No email / +39095 7262165

Status: Recruiting

Ospedale San Raffaele. ( Site 2106)

Milan, 20132, Italy

No email / +39 0226438003

Status: Recruiting

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlin-DEPARTMENT OF EXPERIMENTAL, DIAGNOSTIC ( Site 2105)

Bologna, Emilia-Romagna, 40138, Italy

No email / +390512144626

Status: Recruiting

Fondazione IRCCS San Gerardo dei Tintori-Oncologia ( Site 2111)

Monza, Lombardy, 20900, Italy

No email / +390392339550

Status: Recruiting

Ospedale Humanitas San Pio X ( Site 2113)

Milan, Lombardy, 20159, Italy

No email / +390269517533

Status: Recruiting

Humanitas University ( Site 2112)

Rozzano, Milano, 20089, Italy

No email / +390282244080

Status: Recruiting

Ospedale Mauriziano-SCDU ONCOLOGIA MEDICA ( Site 2100)

Turin, Piedmont, 10128, Italy

No email / +39 0115082277

Status: Recruiting

Niigata Cancer Center Hospital ( Site 5100)

Niigata, 951-8566, Japan

No email / +81-25-266-5111

Status: Recruiting

Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 5103)

Osaka, 541-8567, Japan

No email / +81-6-6945-1181

Status: Recruiting

Kurume University Hospital ( Site 5105)

Kurume, Fukuoka, 830-0011, Japan

No email / +81-942-35-3311

Status: Recruiting

Gunma Prefectural Cancer Center ( Site 5116)

Ohta, Gunma, 373-8550, Japan

No email / +81-276-38-0771

Status: Recruiting

Hokkaido University Hospital ( Site 5106)

Sapporo, Hokkaido, 060-8648, Japan

No email / +81-11-716-1161

Status: Recruiting

Iwate Medical University Hospital ( Site 5112)

Shiwa-gun, Iwate, 028-3695, Japan

No email / +81-19-613-7111

Status: Recruiting

Cancer Institute Hospital of JFCR ( Site 5111)

Koto, Tokyo, 135-8550, Japan

No email / +81-3-3520-0111

Status: Recruiting

The Jikei University Hospital ( Site 5118)

Minato, Tokyo, 105-8471, Japan

No email / +81-3-3433-1111

Status: Recruiting

Pantai Hospital Kuala Lumpur ( Site 3100)

Kuala Lumpur, 59100, Malaysia

No email / +60327814519

Status: Recruiting

Centro de Atención e Investigación Cardiovascular del Potosí ( Site 0506)

San Luis Potosí City, 78200, Mexico

No email / +52 4448340596

Status: Recruiting

Centro de Investigación Oncológica Galerías SC ( Site 0508)

Aguascalientes, 20124, Mexico

No email / +52 5527280926

Status: Recruiting

CENEIT Oncologicos ( Site 0507)

Mexico City, Mexico City, 03100, Mexico

No email / (+52) 55-5534-2400

Status: Recruiting

Centro de Investigacion Clinica de Oaxaca ( Site 0505)

Oaxaca City, Oaxaca, 68020, Mexico

No email / +529512570569

Status: Recruiting

University Medical Center Groningen ( Site 2204)

Groningen, 9713 GZ, Netherlands

No email / 31503612821

Status: Recruiting

Radboudumc-Medical Oncology ( Site 2202)

Nijmegen, Gelderland, 6525 GA, Netherlands

No email / 31243618800

Status: Recruiting

Catharina Ziekenhuis-Oncology ( Site 2203)

Eindhoven, North Brabant, 5623 EJ, Netherlands

No email / 31402396622

Status: Recruiting

Amsterdam UMC, locatie VUmc ( Site 2201)

Amsterdam, North Holland, 1081 HV, Netherlands

No email / 31204444321

Status: Recruiting

Erasmus Medisch Centrum-Medical Oncology ( Site 2200)

Rotterdam, South Holland, 3015 GD, Netherlands

No email / 31107034897

Status: Recruiting

UPR Comprehensive Cancer Center-Comprehensive Cancer Center Hospital ( Site 0601)

San Juan, 00935, Puerto Rico

No email / 7877728300 EXT 1226

Status: Recruiting

National Cancer Centre Singapore ( Site 3300)

Singapore, Central Singapore, 168583, Singapore

No email / +6564368000

Status: Recruiting

Skånes Universitetssjukhus Lund-Department of Hematology ( Site 2602)

Lund, Skåne County, 221 85, Sweden

No email / +4646171000

Status: Recruiting

Universitetssjukhuset i Linköping ( Site 2600)

Linköping, Östergötland County, 581 85, Sweden

No email / +46101030000

Status: Recruiting

St James's University Hospital ( Site 2804)

Leeds, LS9 7TF, United Kingdom

No email / 01132068628

Status: Recruiting

The Christie NHS Foundation Trust-Research and Development ( Site 2802)

Manchester, m20 4bx, United Kingdom

No email / 01619187682

Status: Recruiting

ROYAL MARSDEN HOSPITAL (CHELSEA)-Gynaecology Research Centre ( Site 2807)

London, England, SW10 9NH, United Kingdom

No email / +442078118311

Status: Recruiting

University College London Hospital ( Site 2805)

London, London, City of, NW1 2PG, United Kingdom

No email / +442034567890

Status: Recruiting

USA Mitchell Cancer Institute-Clinical Trials ( Site 4126)

Mobile, Alabama, 36604, United States

No email / 251-665-8000

Status: Recruiting

Providence Alaska Medical Center ( Site 4137)

Anchorage, Alaska, 99508, United States

No email / 907-562-2211

Status: Recruiting

HonorHealth (HH) ( Site 8002)

Phoenix, Arizona, 85016, United States

No email / 623-580-5800

Status: Recruiting

Hoag Memorial Hospital Presbyterian ( Site 4104)

Newport Beach, California, 92663, United States

No email / 949-764-4624

Status: Recruiting

Moores Cancer Center-Clinical Trials Office - Gynecological Oncology ( Site 4125)

La Jolla, California, 92093, United States

No email / 626-644-3712

Status: Recruiting

UCLA Hematology/Oncology - Westwood (Building 100)-Department of OBGYN, Division of Gynecologic Onc ( Site 4105)

Los Angeles, California, 90095, United States

No email / 310-794-7274

Status: Recruiting

Advent Health ( Site 4140)

Orlando, Florida, 32804, United States

No email / 407-303-2422

Status: Recruiting

Florida Cancer Specialists East ( Site 7001)

West Palm Beach, Florida, 33401, United States

No email / 602-300-0138

Status: Recruiting

Mount Sinai Comprehensive Cancer Center ( Site 4143)

Miami Beach, Florida, 33140, United States

No email / 305-674-2625

Status: Recruiting

Lewis Cancer and Research Pavilion ( Site 4114)

Savannah, Georgia, 31405, United States

No email / 912-819-5704

Status: Recruiting

University Medical Center New Orleans ( Site 4132)

New Orleans, Louisiana, 70112, United States

No email / 504-568-4850

Status: Recruiting

Willis Knighton Medical Center ( Site 4101)

Shreveport, Louisiana, 71103, United States

No email / 318-408-1198

Status: Recruiting

The Center of Hope ( Site 4106)

Reno, Nevada, 89511, United States

No email / 775-327-4673

Status: Recruiting

Holy Name Medical Center ( Site 4117)

Teaneck, New Jersey, 07666, United States

No email / 201-227-6200

Status: Recruiting

Optimum Clinical Research Group ( Site 4138)

Albuquerque, New Mexico, 87109, United States

No email / 505-843-7813

Status: Recruiting

Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 4121)

New York, New York, 10016, United States

No email / 212-731-6000

Status: Recruiting

Perlmutter Cancer Center NYU Langone Hospital - Long Island ( Site 4145)

Mineola, New York, 11501, United States

No email / 212-731-6000

Status: Recruiting

Duke Cancer Institute ( Site 4120)

Durham, North Carolina, 27710, United States

No email / 919-684-3780

Status: Recruiting

The Ohio State University ( Site 4103)

Hilliard, Ohio, 43026, United States

No email / 614-293-4376

Status: Recruiting

University of Cincinnati Medical Center ( Site 4128)

Cincinnati, Ohio, 45219, United States

No email / 513-584-7698

Status: Recruiting

Oklahoma Cancer Specialists and Research Institute, LLC-Clinical Research ( Site 4116)

Tulsa, Oklahoma, 74146, United States

No email / 918-505-3200

Status: Recruiting

Legacy Good Samaritan Medical Center-Oncology Clinical Research ( Site 4115)

Portland, Oregon, 97210, United States

No email / 503-413-8199

Status: Recruiting

Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8007)

Eugene, Oregon, 97401, United States

No email / 360-449-6521

Status: Recruiting

Asplundh Cancer Pavilion ( Site 4113)

Willow Grove, Pennsylvania, 19090, United States

No email / 215-481-4429

Status: Recruiting

Sidney Kimmel Cancer Center - Jefferson Health ( Site 4142)

Philadelphia, Pennsylvania, 19107, United States

No email / 215-481-4429

Status: Recruiting

The West Clinic, PLLC dba West Cancer Center ( Site 4108)

Germantown, Tennessee, 38138, United States

No email / 901-683-0055

Status: Recruiting

Houston Methodist Hospital OB/GYN ( Site 4102)

Houston, Texas, 77030, United States

No email / 713-441-6616

Status: Recruiting

Texas Oncology - Central/South Texas ( Site 8010)

Austin, Texas, 78731, United States

No email / 512-427-9400

Status: Recruiting

Texas Oncology - DFW ( Site 8003)

Fort Worth, Texas, 76104, United States

No email / 817-413-1500

Status: Recruiting

Texas Oncology - Gulf Coast ( Site 8008)

Webster, Texas, 77598, United States

No email / 281-332-7505

Status: Recruiting

Texas Oncology - Northeast Texas ( Site 8009)

Tyler, Texas, 75702, United States

No email / 903-579-9800

Status: Recruiting

Texas Oncology - San Antonio ( Site 8006)

San Antonio, Texas, 78240, United States

No email / 210-595-5300

Status: Recruiting

Inova Schar Cancer Institute ( Site 4139)

Fairfax, Virginia, 22031-4867, United States

No email / 703-933-8125

Status: Recruiting

University of Virginia Cancer Center ( Site 4123)

Charlottesville, Virginia, 22908, United States

No email / 434-943-9333

Status: Recruiting

Swedish Medical Center-Swedish Cancer Institute ( Site 4134)

Seattle, Washington, 98104, United States

No email / 206-965-1700

Status: Recruiting